September Launch Eyed For Cephalon/J&J’s Sparlon

Cephalon plans to launch the attention deficit/hyperactivity disorder treatment Sparlon (modafinil) with partner Johnson & Johnson in September to take advantage of students returning to school, provided FDA approves the product by its Aug. 22 user fee date, Cephalon said